PDL BioPharma Announces Conversion Rate Adjustments for Convertible Notes
INCLINE VILLAGE, Nev., Dec. 4, 2013 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that the adjusted conversion rate for the:
- 3.75% Convertible Senior Notes due May 1, 2015 (May 2015 Notes), is 159.9165 shares of common stock per $1,000 principal amount or approximately $6.25 per share, effective December 3, 2013; and
- 2.875% Series 2012 Convertible Senior Notes due February 15, 2015 (Series 2012 Notes), is 182.598 shares of common stock per $1,000 principal amount or approximately $5.48 per share, effective December 3, 2013.
The conversion rates for the notes are adjusted in connection with the regular quarterly dividend of $0.15 to be paid on December 12, 2013, to all stockholders who own shares of PDL on December 5, 2013, the record date.
May 2015 Notes
The conversion rate for the May 2015 Notes was previously 157.3700 shares of common stock per $1,000 principal amount of the May 2015 Notes. In connection with a cash dividend, the conversion rate is increased by multiplying the previous conversion rate by a fraction, the numerator of which is the average closing price of PDL's common stock for the 10 consecutive trading days immediately preceding the ex-dividend date of December 3, 2013, for the cash dividend, and the denominator of which is such average closing price minus the per share dividend amount.
Series 2012 Notes
The conversion rate for the Series 2012 Notes was previously 179.777 shares of common stock per $1,000 principal amount of the Series 2012 Notes. In connection with a cash dividend, the conversion rate is increased by multiplying the previous conversion rate by a fraction, the numerator of which is the average closing price of PDL's common stock for the five consecutive trading days immediately preceding the ex-dividend date of December 3, 2013, for the cash dividend, and the denominator of which is such average closing price minus the per share dividend amount.
About PDL BioPharma
PDL BioPharma manages a portfolio of patents and royalty assets, consisting primarily of its Queen et al. antibody humanization patents and license agreements with various biotechnology and pharmaceutical companies. PDL pioneered the humanization of monoclonal antibodies and, by doing so, enabled the discovery of a new generation of targeted treatments for cancer and immunologic diseases for which it receives significant royalty revenue. PDL is currently focused on intellectual property asset management, investing in new income generating assets, and maximizing value for its shareholders.
The company was formerly known as Protein Design Labs, Inc. and changed its name to PDL BioPharma, Inc. in 2006. PDL was founded in 1986 and is headquartered in Incline Village, Nevada.
In 2011, PDL initiated a strategy to bring in new income generating assets from the healthcare sector. To accomplish this goal, PDL seeks to provide non-dilutive growth capital and financing solutions to late stage public and private healthcare companies and offers immediate financial monetization of royalty streams to companies, academic institutions, and inventors. PDL successfully executed on this strategy by deploying approximately $500 million to date and continues to pursue this strategic initiative. PDL is focused on the quality of the income generating assets and potential returns on investment.
For more information, please visit www.pdl.com.
NOTE: PDL BioPharma and the PDL BioPharma logo are considered trademarks of PDL BioPharma, Inc.
The foregoing statements regarding PDL's intentions with respect to the cash dividend payment described above constitute "forward looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Important factors that could impair the value of the Company's royalty assets and limit the Company's ability to pay dividends are disclosed in the risk factors contained in the Company's 2012 Annual Report on Form 10K filed with the Securities and Exchange Commission on March 1, 2013. All forward looking statements are expressly qualified in their entirety by such factors. We do not undertake any duty to update any forward looking statement except as required by law.
SOURCE PDL BioPharma, Inc.